Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Katrin Friedrich is active.

Publication


Featured researches published by Katrin Friedrich.


Proteomics | 2014

Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin-fixed paraffin-embedded tissues.

Rita Casadonte; Mark Kriegsmann; Friederike Zweynert; Katrin Friedrich; Gustavo Bretton; Mike Otto; Sören-Oliver Deininger; Rainer Paape; Eckhard Belau; Detlev Suckau; Daniela Aust; Christian Pilarsky; Jörg Kriegsmann

Diagnosis of the origin of metastasis is mandatory for adequate therapy. In the past, classification of tumors was based on histology (morphological expression of a complex protein pattern), while supportive immunohistochemical investigation relied only on few “tumor specific” proteins. At present, histopathological diagnosis is based on clinical information, morphology, immunohistochemistry, and may include molecular methods. This process is complex, expensive, requires an experienced pathologist and may be time consuming. Currently, proteomic methods have been introduced in various clinical disciplines. MALDI imaging MS combines detection of numerous proteins with morphological features, and seems to be the ideal tool for objective and fast histopathological tumor classification. To study a special tumor type and to identify predictive patterns that could discriminate metastatic breast from pancreatic carcinoma MALDI imaging MS was applied to multitissue paraffin blocks. A statistical classification model was created using a training set of primary carcinoma biopsies. This model was validated on two testing sets of different breast and pancreatic carcinoma specimens. We could discern breast from pancreatic primary tumors with an overall accuracy of 83.38%, a sensitivity of 85.95% and a specificity of 76.96%. Furthermore, breast and pancreatic liver metastases were tested and classified correctly.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2004

Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck

Susanne Koy; Martin Hauses; Hella Appelt; Katrin Friedrich; Hans K. Schackert; Uwe Eckelt

ZAC/Lot1 is a previously identified candidate tumor suppressor gene. The gene maps to the human chromosome 6q24‐q25, a region frequently deleted in squamous cell carcinomas of the head and neck and other solid tumors.


Breast Cancer Research | 2012

Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression

Maryam Rezaei; Katrin Friedrich; Ben Wielockx; Aleksandar Kuzmanov; Antje Kettelhake; Myriam Labelle; Hans Schnittler; Gustavo Baretton; Georg Breier

IntroductionDeregulation of cadherin expression, in particular the loss of epithelial (E)-cadherin and gain of neural (N)-cadherin, has been implicated in carcinoma progression. We previously showed that endothelial cell-specific vascular endothelial (VE)-cadherin can be expressed aberrantly on tumor cells both in human breast cancer and in experimental mouse mammary carcinoma. Functional analyses revealed that VE-cadherin promotes tumor cell proliferation and invasion by stimulating transforming growth factor (TGF)-β signaling. Here, we investigate the functional interplay between N-cadherin and VE-cadherin in breast cancer.MethodsThe expression of N-cadherin and VE-cadherin was evaluated by immunohistochemistry in a tissue microarray with 84 invasive human breast carcinomas. VE-cadherin and N-cadherin expression in mouse mammary carcinoma cells was manipulated by RNA interference or overexpression, and cells were then analyzed by immunofluorescence, reverse transcriptase-polymerase chain reaction, and western blot. Experimental tumors were generated by transplantation of the modified mouse mammary carcinoma cells into immunocompetent mice. Tumor growth was monitored, and tumor tissue was subjected to histological analysis.ResultsVE-cadherin and N-cadherin were largely co-expressed in invasive human breast cancers. Silencing of N-cadherin in mouse mammary carcinoma cells led to decreased VE-cadherin expression and induced changes indicative of mesenchymal-epithelial transition, as indicated by re-induction of E-cadherin, localization of β-catenin at the cell membrane, decreased expression of vimentin and SIP1, and gain of epithelial morphology. Suppression of N-cadherin expression also inhibited tumor growth in vivo, even when VE-cadherin expression was forced.ConclusionsOur results highlight the critical role of N-cadherin in breast cancer progression and show that N-cadherin is involved in maintaining the malignant tumor cell phenotype. The presence of N-cadherin prevents the re-expression of E-cadherin and localization of β-catenin at the plasma membrane of mesenchymal mammary carcinoma cells. N-cadherin is also required to maintain the expression of VE-cadherin in malignant tumor cells but not vice versa. Thus, N-cadherin acts in concert with VE-cadherin to promote tumor growth.


Histopathology | 2010

Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.

Matthias Kotzsch; Katharina Bernt; Katrin Friedrich; Elvira Luther; Sybille Albrecht; Axel Gatzweiler; Viktor Magdolen; Gustavo Baretton; Christian Zietz; Thomas Luther

Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, Magdolen V, Baretton G, Zietz C & Luther T
(2010) Histopathology 57, 461–471
Prognostic relevance of tumour cell‐associated uPAR expression in invasive ductal breast carcinoma


Pathology Research and Practice | 1995

Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers

Katrin Friedrich; Volker Dimmer; Gunter Haroske; A. Loßnitzer; M. Kasper; Franz Theissig; K.D. Kunze

The expression of p53 and bcl-2 was immunohistochemically investigated in 61 formalin-fixed, paraffin-embedded invasive breast carcinomas. The study was aimed to elucidate the relationship between both markers and the correlation of p53 and bcl-2, respectively, to clinicopathological variables, to hormone receptor status and to DNA-ploidy. Twenty tumors showed a positive reaction with the monoclonal antibody DO-1 against p53 protein. Its immunohistochemical demonstration was significantly correlated with a tumor size larger than 2 cm, a low estrogen receptor status and DNA-aneuploidy. Bcl-2 was demonstrated in 51 breast cancers. Bcl-2 was preferably seen in low grade and hormone receptor positive tumors. We found a negative correlation between the immunoreactive scores of p53 and bcl-2, but in 17 carcinomas a coexpression of both proteins was seen. Cases with this coexpression did not differ significantly from the other tumors in clinicopathological parameters. In eight of these cases more than 10% of the cells were found to be positive for both markers. In four cases we could show many cells to exhibit both markers as it was assessed by an immunofluorescence double labeling technique.


BMC Cancer | 2012

Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature

Karin Kast; Mechthild Krause; Markus Schuler; Katrin Friedrich; Barbara Thamm; Andrea Bier; W. Distler; Stefan Krüger

BackgroundLi-Fraumeni-Syndrome (LFS) is an autosomal-dominant, inherited tumour predisposition syndrome associated with heterozygous germline mutations in the TP53 gene. Patients with LFS are at a high risk to develop early-onset breast cancer and multiple malignancies, among which sarcomas are the most common. A high incidence of childhood tumours and close to 100% penetrance has been described. Knowledge of the genetic status of the TP53 gene in these patients is critical not only due to the increased risk of malignancies, but also because of the therapeutic implications, since a higher rate of radiation-induced secondary tumours in these patients has been observed.Case reportWe report a patient with LFS harbouring heterozygous, pathogenic TP53 germline mutation, who was affected by four synchronous malignancies at the age of 40: a myxofibrosarcoma of the right upper arm, bilateral breast cancer and a periadrenal liposarcoma. Radiological treatments and a surveillance program were adjusted according to recommendations for LFS patients.ConclusionManagement of tumour treatment of patients with LFS is different to the general population because of their risk for secondary cancers in the radiation field. Screening procedures should take a possibly elevated risk for radiation induced cancer into account.


Journal of Proteome Research | 2014

Identification and functional validation of RAD23B as a potential protein in human breast cancer progression.

Annett Linge; Priyanka Maurya; Katrin Friedrich; Gustavo Baretton; Shane Kelly; Michael Henry; Martin Clynes; Annemarie Larkin; Paula Meleady

Identification of protein targets that play a role in breast cancer invasion may help to understand the rapid progression of cancer and may lead to the development of new biomarkers for the disease. In this study, we compared two highly invasive and two poorly invasive breast cancer cell lines using comparative label-free LC-MS profiling in order to identify differentially expressed proteins that may be linked to the invasive phenotype in vitro. Forty-five proteins were found to be upregulated, and 34 proteins, downregulated. UV excision repair protein RAD23 homologue B (RAD23B) was found among the downregulated proteins in highly invasive breast cancer cell lines. In poorly invasive breast cancer cell lines, siRNA-mediated downregulation of RAD23B subsequently led to an increase in invasion and adhesion in vitro. Immunohistochemistry analysis of 164 specimens of invasive breast cancer showed that having a high percentage (>80%) of RAD23B positive nuclei was significantly associated with histopathological grades 1 and 2 breast cancer and with low mitotic activity. In addition, a high staining intensity for RAD23B in the cytoplasm was significantly associated with histopathological grade 3 breast cancer. This study suggests a potential role of RAD23B in breast cancer progression and may further imply a tumor suppressor role of nuclear RAD23B in breast cancer.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2008

MICROSATELLITE INSTABILITY AND LOSS OF HETEROZYGOSITY IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Susanne Koy; Jens Plaschke; Hella Luksch; Katrin Friedrich; Eberhard Kuhlisch; Uwe Eckelt; Ramon Martinez

Microsatellite instability (MSI) in head and neck squamous cell carcinoma (HNSCC) has been reported with a wide range of frequencies. The aim of our study was to disclose the frequency and basis of MSI in HNSCC and to correlate MSI and findings on loss of heterozygosity (LOH) with the clinical data.


Analytical Cellular Pathology | 2008

Chromosomal genotype in breast cancer progression: Comparison of primary and secondary manifestations

Katrin Friedrich; Theresa Weber; Jens Scheithauer; Wolfdietrich Meyer; Gunter Haroske; Klaus Kunze; Gustavo Baretton

The purpose of this study was to compare the chromosomal genotype between breast cancers with and without secondary manifestations and between primary tumors and their secondary manifestations. Eighty six breast cancers, twenty lymph node metastases, ten distant metastases and ten local recurrences were analyzed by comparative genomic hybridization. Tumors with local recurrences showed significant more frequent losses at 2q32 than the tumors without recurrences. Lymph node positive cases showed significant more frequent losses at 9p21 than node negative cases. Lymph node metastases exhibited significant more frequent losses at 7q11, 14q24.3–q31 and 17q22–q24 than their primary tumors. In cases with distant metastases, losses at 5q23 were more frequent than in those without, but not reaching the significance level. The distant metastases showed significant more frequent losses at 5p15, 12q24 and 17q22–q24 than the primary tumors. These results reveal strong evidence that the potential for progression is determined in the primary tumor and that different ways of the development of local recurrences, lymph node and distant metastases exist. After confirmation of the results by interphase FISH on tissue micro arrays, the detection of these specific chromosomal imbalances may contribute to a more individual prediction of prognosis in breast cancer.


Histochemistry and Cell Biology | 1996

NUCLEAR IMAGE ANALYSIS OF IMMUNOHISTOCHEMICALLY STAINED CELLS IN BREAST CARCINOMAS

Gunter Haroske; Volker Dimmer; Katrin Friedrich; Wolfdietrich Meyer; Berit Thieme; Franz Theissig; Klaus Kunze

Hitherto, the relationship between malignancy-associated morphological features in single tumour cells and the expression of markers indicating functional properties of these cells remained widely unknown. This study was aimed at describing differences in the size, shape and chromatin structure between tumour cells with different marker expression for progesterone receptors (PgR) and p53. Two series of breast cancers, consisting of 50 PgR-positive, and 39 p53-negative and 49 p53-positive mammary carcinomas, were investigated. The immunohistochemical staining was performed on paraffin sections using 3-amino-9-ethylcarbazole as the chromogenic substrate. By means of a cytometry workstation equipped with a computer-controlled motorised scanning stage, about 500 positive and negative tumour cells in each case were localised in the microscope and categorised by a scoring system for their staining intensity. After destaining, the tissue sections were Feulgen-stained. Then, all the tumour cells were relocated automatically and analysed by high resolution image cytometry. Among the numerous size, shape, and texture features used in the system, several variables of the nuclear contour and chromatin structure were found to be significantly different between the positive and negative tumour cell populations. Nuclei without PgR had more malignancy-associated morphological features than PgR-positive cells. Whereas p53-negative nuclei had a higher degree of regularity, their positive counterparts exhibited higher DNA ploidy values.

Collaboration


Dive into the Katrin Friedrich's collaboration.

Top Co-Authors

Avatar

Gustavo Baretton

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Gunter Haroske

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Wolfdietrich Meyer

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Franz Theissig

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Klaus Kunze

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Volker Dimmer

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Axel Gatzweiler

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Pauline Wimberger

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Theresa Link

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar

Georg Breier

Dresden University of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge